Vascular endothelial growth factor (VEGF) signaling in tumor progression.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Critical reviews in oncology/hematology

• Publication date

  2007-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.CRITREVONC.2007.01.006PMID 17324579
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor angiogenesis

  2020influential reference
• Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

  2007cited by this paper
• Targeting VEGF-A to treat cancer and age-related macular degeneration.

  2007cited by this paper
• Do ut des

  2007cited by this paper
• Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression.

  2006cited by this paper
• Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia.

  2006cited by this paper
• Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis.

  2006cited by this paper
• Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.

  2006influential reference
• Crystal structure of human vascular endothelial growth factor-B: identification of amino acids important for receptor binding.

  2006cited by this paper
• The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells.

  2006cited by this paper
• Predicting benefit from anti-angiogenic agents in malignancy

  2006cited by this paper
• Sunitinib: a newly approved small-molecule inhibitor of angiogenesis.

  2006cited by this paper
• VEGF receptor signalling ? in control of vascular function

  2006cited by this paper
• Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy

  2006cited by this paper
• Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

  2006cited by this paper
• Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration.

  2006influential reference
• Cross-species Vascular Endothelial Growth Factor (VEGF)-blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF*

  2006cited by this paper
• Mechanisms of hypertension associated with BAY 43-9006.

  2006cited by this paper
• Antiangiogenic peptides and proteins: from experimental tools to clinical drugs.

  2006influential reference
• The neuropilins and their role in tumorigenesis and tumor progression.

  2006cited by this paper
• The hypoxia‐inducible‐factor hydroxylases bring fresh air into hypoxia signalling

  2006cited by this paper
• VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature.

  2006cited by this paper
• Functional interaction of VEGF‐C and VEGF‐D with neuropilin receptors

  2006influential reference
• Expression of vascular endothelial growth factor (VEGF)-C and -D in gastric carcinoma

  2006cited by this paper
• Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.

  2006cited by this paper
• Tumor hypoxia and cancer progression.

  2006influential reference
• Biology of vascular endothelial growth factors

  2006cited by this paper
• Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.

  2006cited by this paper
• New antiangiogenetic agents and non-small cell lung cancer.

  2006cited by this paper
• Lessons from phase III clinical trials on anti-VEGF therapy for cancer

  2006cited by this paper
• Neuropilin-1 is involved in regulation of apoptosis and migration of human colon cancer.

  2006cited by this paper
• Making the cut: protease-mediated regulation of angiogenesis.

  2006cited by this paper
• Regulation of angiogenesis by hypoxia-inducible factor 1.

  2006influential reference
• Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling.

  2006cited by this paper
• Placental but Not Heart Defects Are Associated with Elevated Hypoxia-Inducible Factor α Levels in Mice Lacking Prolyl Hydroxylase Domain Protein 2

  2006influential reference
• Neuropilins in neoplasms: expression, regulation, and function.

  2006influential reference
• The role of neuropilins in cancer

  2006influential reference
• The placenta growth factor in skin angiogenesis.

  2006cited by this paper
• Plasmin modulates vascular endothelial growth factor-A-mediated angiogenesis during wound repair.

  2006cited by this paper
• Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

  2006cited by this paper
• Cardiac expression of placental growth factor predicts the improvement of chronic phase left ventricular function in patients with acute myocardial infarction.

  2006cited by this paper
• The safety of bevacizumab

  2006cited by this paper
• Pericytes and vascular stability.

  2006cited by this paper
• Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm).

  2006cited by this paper
• The biology of vascular endothelial growth factors.

  2005cited by this paper
• Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1.

  2005influential reference
• Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells.

  2005cited by this paper
• Mechanisms underlying differential responses to FGF signaling.

  2005cited by this paper
• Oncogenes as Novel Targets for Cancer Therapy (Part I)

  2005cited by this paper
• Vascular Endothelial Growth Factor D Is Dispensable for Development of the Lymphatic System

  2005cited by this paper
• Placenta growth factor is over-expressed and has prognostic value in human breast cancer.

  2005cited by this paper
• Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion.

  2005cited by this paper
• Heparin Regulates Vascular Endothelial Growth Factor165-dependent Mitogenic Activity, Tube Formation, and Its Receptor Phosphorylation of Human Endothelial Cells

  2005influential reference
• Adult 'endothelial progenitor cells'. Renewing vasculature.

  2005cited by this paper
• Expression of Placenta growth factor (PlGF) in non-Small cell Lung cancer (NSCLC) and the clinical and prognostic significance

  2005cited by this paper
• Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens.

  2005cited by this paper
• p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.

  2005cited by this paper
• Contribution of bone marrow-derived cells to blood vessels in ischemic tissues and tumors.

  2005cited by this paper
• VEGF receptor‐2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis

  2005cited by this paper
• Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.

  2005cited by this paper
• Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.

  2005cited by this paper
• Angiogenesis: update 2005

  2005cited by this paper
• Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors

  2005influential reference
• Molecular mechanisms of tumor vascularization.

  2005influential reference
• Endothelial cells and VEGF in vascular development

  2005cited by this paper
• Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells

  2005cited by this paper
• A peptide corresponding to the neuropilin-1-binding site on VEGF165 induces apoptosis of neuropilin-1-expressing breast tumour cells

  2005cited by this paper
• VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche

  2005influential reference
• MAP kinase pathways

  2005cited by this paper
• VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma

  2005cited by this paper
• Vascular Endothelial Growth Factor and Angiogenesis

  2004influential reference
• Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis.

  2004cited by this paper
• A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma.

  2004cited by this paper
• HB-EGF Is a Potent Inducer of Tumor Growth and Angiogenesis

  2004influential reference
• The urokinase plasminogen activator system: role in malignancy.

  2004cited by this paper
• The Adaptor Protein Shb Binds to Tyrosine 1175 in Vascular Endothelial Growth Factor (VEGF) Receptor-2 and Regulates VEGF-dependent Cellular Migration*

  2004cited by this paper
• Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins

  2004influential reference
• Constitutive and inducible expression and regulation of vascular endothelial growth factor.

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004influential reference
• Vascular endothelial growth factor receptor 3 in hypoxia‐induced vascular development

  2004cited by this paper
• Catalytic Properties of the Asparaginyl Hydroxylase (FIH) in the Oxygen Sensing Pathway Are Distinct from Those of Its Prolyl 4-Hydroxylases*

  2004cited by this paper
• Bone marrow-Derived Cells Do Not Incorporate Into the Adult Growing Vasculature

  2004cited by this paper
• Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity.

  2004influential reference
• Stimulation of angiogenesis by Ras proteins.

  2004cited by this paper
• Expression of Neuropilin-1 in High-grade Dysplasia, Invasive Cancer, and Metastases of the Human Gastrointestinal Tract

  2004cited by this paper
• Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis.

  2004cited by this paper
• Neutralizing VEGF bioactivity with a soluble chimeric VEGF‐receptor protein flt(1‐3)IgG inhibits testosterone‐stimulated prostate growth in castrated mice

  2004cited by this paper
• Regulation of vascular endothelial growth factor expression in human gastric cancer cells by interleukin-1beta.

  2004cited by this paper
• Review Principles of Tumor Suppression Erties of " Classic " Tumor Suppressor Genes. First, They

  2004cited by this paper
• Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma.

  2004cited by this paper
• The Crystal Structure of Placental Growth Factor in Complex with Domain 2 of Vascular Endothelial Growth Factor Receptor-1*

  2004cited by this paper
• Aberrant Expression of Neuropilin-1 and -2 in Human Pancreatic Cancer Cells

  2004cited by this paper
• Semaphorin-3F Is an Inhibitor of Tumor Angiogenesis

  2004cited by this paper
• Vascular endothelial growth factor: basic science and clinical progress.

  2004influential reference
• The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer.

  2004cited by this paper
• Hypoxia activates matrix metalloproteinase expression and the VEGF system in monkey choroid-retinal endothelial cells: Involvement of cytosolic phospholipase A2 activity.

  2004cited by this paper
• Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect.

  2004cited by this paper
• Activin A stimulates vascular endothelial growth factor gene transcription in human hepatocellular carcinoma cells.

  2004cited by this paper
• Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin‐1 by epidermal growth factor in human pancreatic carcinoma

  2003cited by this paper
• Transforming Growth Factor β1 Stimulates Vascular Endothelial Growth Factor Gene Transcription in Human Cholangiocellular Carcinoma Cells

  2003cited by this paper

• Tumor-Associated Macrophages in Lung Cancer: Origins, Functional Heterogeneity, and Therapeutic Implications

  2025cites this paper
• Computational analysis of miRNA mediated KDR gene regulation and natural VEGFR2 inhibitors from Persicaria hydropiper in hepatocellular carcinoma

  2025cites this paper
• Infections with Chlamydia pneumoniae and SARS-CoV-2 and Alzheimer’s disease pathogenesis

  2025cites this paper
• Vascular endothelial cells and angiogenesis.

  2025cites this paper
• Cross-family interactions of vascular endothelial growth factors and platelet-derived growth factors on the endothelial cell surface: A computational model

  2025cites this paper
• New highlights in cancer and depression multimorbidity: a scoping systematic review

  2025cites this paper
• Identification of Novel Thiazolyl-1,2,3-Triazole Hybrids as Potent VEGFR-2 Inhibitors for Breast Cancer Treatment

  2025cites this paper
• miR-205: A dual regulator of angiogenesis in health and disease (Review)

  2025cites this paper
• Decoding estrogen receptor and GPER biology: structural insights and therapeutic advances in ERα−positive breast cancer

  2025cites this paper
• Unveiling novel VEGFR-2 inhibitors: QSAR modeling, Molecular docking, MD and MM-GBSA calculations, pharmacokinetics profiling and DFT studies

  2025cites this paper
• Biodegradable ionic nanoregulators for synchronous modulation of copper and iron ion homeostasis in breast cancer therapy

  2025cites this paper
• Nutraceuticals in breast cancer therapy: Mechanistic insights and therapeutic potential.

  2025cites this paper
• Targeting skeletal interoception: a novel mechanistic insight into intervertebral disc degeneration and pain management

  2025cites this paper
• Molecular crosstalk between GPCR and receptor tyrosine-protein kinase in neuroblastoma: molecular mechanism and therapeutic implications

  2025cites this paper
• Tailoring imaging probes for defining glioma invasive margins: Tracing the molecular footprints of cancer cells.

  2025cites this paper
• Modulation of prostaglandin-endoperoxide synthase-2 (PTGS2) mediated VEGF-signalling pathway by oral metronomic chemotherapy in locally advanced oral squamous cell Carcinoma: A brief report

  2025cites this paper
• LinTT1-Functionalized Hybrid Lipid-Polymer Nanoparticles for Glioblastoma Targeting.

  2025cites this paper
• Synthesis and properties of five-membered heterocycles containing two exocyclic conjugated double bonds

  2025cites this paper
• Directing Cancer-Related Angiogenesis: Progressive E-Pharmacophore Modelling of Novel Selective VEGFR-1 Inhibitors

  2025cites this paper
• A Coordination Nanosystem Enables Endogenous Ferric Ion-Initiated Multi-Catalysis for Synergistic Tumor-Specific Ferroptosis and Gene Therapy.

  2025cites this paper
• New pyrano-pyridine conjugates as potential anticancer agents: design, synthesis and computational studies.

  2024cites this paper
• Design and In Silico and In Vitro Evaluations of a Novel Nicotinamide Derivative as a VEGFR-2 Inhibitor

  2024cites this paper
• Targeted Glioma Therapy—Clinical Trials and Future Directions

  2024cites this paper
• Current progress and prospects for G protein-coupled estrogen receptor in triple-negative breast cancer

  2024cites this paper
• Improved lymphangiogenesis around vascularized lymph node flaps by periodic injection of hyaluronidase in a rodent model

  2024cites this paper
• Comprehensive review of signaling pathways and therapeutic targets in gastrointestinal cancers.

  2024cites this paper
• PICALM as a Novel Prognostic Biomarker and Its Correlation with Immune Infiltration in Breast Cancer

  2024cites this paper
• Elevated VEGF-A Levels in the Aqueous Humor of Patients With Primary Open Angle Glaucoma

  2024cites this paper
• Recent advances and future directions on small molecule VEGFR inhibitors in oncological conditions.

  2024cites this paper
• A critical analysis of design, binding pattern and SAR of benzo-fused heteronuclear compounds as VEGFR-2 inhibitors.

  2024cites this paper
• Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment.

  2024cites this paper
• Applications of nanotechnology in remodeling the tumour microenvironment for glioblastoma treatment.

  2024cites this paper
• New 2-oxoindole derivatives as multiple PDGFRα/ß and VEGFR-2 tyrosine kinase inhibitors.

  2024cites this paper
• Structural and dynamical insights revealed the anti-glioblastoma potential of withanolides from Withania coagulans against vascular endothelial growth factor receptor (VEGFR)

  2024cites this paper
• High serum angiopoietin-like protein-4 levels are associated with gestational hypertension and preeclampsia: a case-control study

  2024cites this paper
• Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas.

  2024cites this paper
• The Structure, Functions and Potential Medicinal Effects of Chlorophylls Derived from Microalgae

  2024cites this paper
• Exploring the anticancer properties of a new nicotinamide analogue: Investigations into in silico analysis, antiproliferative effects, selectivity, VEGFR-2 inhibition, apoptosis induction, and migration suppression.

  2023cites this paper
• Ethanol extract of basil (Ocimum Basilicum L.) leaves inhibits endometriosis growth in a mouse model by modulating vascular endothelial growth factor (VEGF) expression

  2023cites this paper
• A Theobromine Derivative with Anticancer Properties Targeting VEGFR‐2: Semisynthesis, in silico and in vitro Studies

  2023cites this paper
• A Comprehensive Review on Targeted Cancer Therapy: New Face of Treatment Approach.

  2023cites this paper
• Monitoring vascular endothelial growth factor-a levels during follow-up after hematopoietic stem cell transplantation in pediatric patients at a Mexican hospital: A pilot study

  2023cites this paper
• Nanoliposomal VEGF-R2 peptide vaccine acts as an effective therapeutic vaccine in a murine B16F10 model of melanoma

  2023cites this paper
• Epigenetic Regulation Interplays with Endometriosis Pathogenesis in Low-Birth-Weight Patients via the Progesterone Receptor B–VEGF-DNMT1 Axis

  2023cites this paper
• VEGFR endocytosis: Implications for angiogenesis.

  2023cites this paper
• Vitamin A, D, E, and K as Matrix Metalloproteinase-2/9 Regulators That Affect Expression and Enzymatic Activity

  2023cites this paper
• Phthalazone tethered 1,2,3-triazole conjugates: In silico molecular docking studies, synthesis, in vitro antiproliferative, and kinase inhibitory activities.

  2023cites this paper
• VEGF levels in the aqueous humor of patients with primary open angle glaucoma: A systematic review and a meta-analysis

  2023cites this paper
• The main biotargets of indole or 2-oxoindole-based hybrids acting as promising antiproliferative agents

  2023influential citation
• Inflammation-Associated Cytotoxic Agents in Tumorigenesis

  2023cites this paper
• Evaluation of VEGF, BDNF, TRKB expression in oral epithelial dysplasia, oral verrucous carcinoma and oral squamous cell carcinoma and their role as prognostic indicator.

  2023cites this paper
• Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States

  2023cites this paper
• Regulatory mechanism and promising clinical application of exosomal circular RNA in gastric cancer

  2023cites this paper
• Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases.

  2023cites this paper
• Exosomal circRNAs: A key factor of tumor angiogenesis and therapeutic intervention.

  2022cites this paper
• (E)-N-(3-(1-(2-(4-(2,2,2-Trifluoroacetamido)benzoyl)hydrazono)ethyl)phenyl)nicotinamide: A Novel Pyridine Derivative for Inhibiting Vascular Endothelial Growth Factor Receptor-2: Synthesis, Computational, and Anticancer Studies

  2022cites this paper
• Modified Benzoxazole-Based VEGFR-2 Inhibitors and Apoptosis Inducers: Design, Synthesis, and Anti-Proliferative Evaluation

  2022cites this paper
• Progress of Noncoding RNA Regulating the Growth and Development of Antler Tissue Research

  2022cites this paper
• Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids.

  2022cites this paper
• Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies

  2022influential citation
• 3D Ultrasound-Guided Photoacoustic Imaging to Monitor the Effects of Suboptimal Tyrosine Kinase Inhibitor Therapy in Pancreatic Tumors

  2022cites this paper
• The impact of VEGF on cancer metastasis and systemic disease.

  2022cites this paper
• Culture of cancer spheroids and evaluation of anti-cancer drugs in 3D-printed miniaturized continuous stirred tank reactors (mCSTRs)

  2022cites this paper
• Context dependent role of p53 during the interaction of hepatocellular carcinoma and endothelial cells.

  2022cites this paper
• Synthesis, Physicochemical and Biological Study of Gallium-68- and Lutetium-177-Labeled VEGF-A165/NRP-1 Complex Inhibitors Based on Peptide A7R and Branched Peptidomimetic

  2022cites this paper
• MMP-9, MMP-2, VEGF and VEGFR-2 as Factors of Invasion and Angiogenesis in Squamous Cell Carcinoma of the Cervix

  2022cites this paper
• Targeted therapy of angiogenesis using anti-VEGFR2 and anti-NRP-1 nanobodies

  2022cites this paper
• Genetic contributions of MHC class I antigen processing and presentation pathway to bladder cancer risk and recurrence.

  2022cites this paper
• Novel EPR-enhanced strategies for targeted drug delivery in pancreatic cancer: An update

  2022cites this paper
• Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors

  2022cites this paper
• Ethoxy-erianin phosphate and afatinib synergistically inhibit liver tumor growth and angiogenesis via regulating VEGF and EGFR signaling pathways.

  2022cites this paper
• 6-amide-2-aryl benzoxazole/benzimidazole derivatives as VEFGR-2 inhibitors in two-and three-dimensional QSAR studies: topomer CoMFA and HQSAR

  2021cites this paper
• G Protein-Coupled Estrogen Receptor in Cancer and Stromal Cells: Functions and Novel Therapeutic Perspectives

  2021cites this paper
• Fatty Acid Composition and Stoichiometry Determine the Angiogenesis Microenvironment

  2021cites this paper
• Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.

  2021cites this paper
• A sensitive spectrophotometric ellipsometry based Aptasensor for the vascular endothelial growth factor detection.

  2021cites this paper
• Nanodrug Delivery Systems Modulate Tumor Vessels to Increase the Enhanced Permeability and Retention Effect

  2021cites this paper
• miRNA regulation of G protein-coupled receptor mediated angiogenic pathways in cancer

  2021cites this paper
• Roles of Therapeutic Bioactive Compounds in Hepatocellular Carcinoma

  2021cites this paper
• The role of TNFTNFα/p53 pathway in endometrial cancer mouse model administered with apple seed extract.

  2021cites this paper
• Intratumoral Canine Distemper Virus Infection Inhibits Tumor Growth by Modulation of the Tumor Microenvironment in a Murine Xenograft Model of Canine Histiocytic Sarcoma

  2021cites this paper
• Targeting the Microenvironment in Esophageal Cancer

  2021cites this paper
• Antiangiogenic and antitumor potential of berbamine, a natural CaMKIIγ inhibitor, against glioblastoma.

  2021cites this paper
• Targeted therapy in esophageal cancer

  2021cites this paper
• US FDA‐Approved Small‐Molecule Kinase Inhibitors for Cancer Therapy

  2021cites this paper
• Strategies for Tracking Immune Surveillance of Tumor Milieu during Angiogenesis

  2021cites this paper
• Biogenesis, cellular effects, and biomarker value of circHIPK3

  2021cites this paper
• Chitosan nanoparticles as a promising candidate for liver injury induced by 2-nitropropane: Implications of P53, iNOS, VEGF, PCNA, and CD68 pathways

  2021cites this paper
• Classical MD and metadynamics simulations on back-pocket binders of CDK2 and VEGFR2: a guidepost to design novel small-molecule dual inhibitors

  2021cites this paper
• Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as anticancer agents and apoptosis inducers

  2021cites this paper
• Knockdown of Malat1 alleviates high-glucose-induced angiogenesis through regulating miR-205-5p/VEGF-A axis.

  2021cites this paper
• The Effect of Novel Medical Nonhormonal Treatments on the Angiogenesis of Endometriotic Lesions

  2021cites this paper
• Vascular Endothelial Growth Factor and Inflammatory Airway Diseases: An Update

  2021cites this paper
• Imaging acute effects of bevacizumab on tumor vascular kinetics in a preclinical orthotopic model of U251 glioma

  2021cites this paper
• Crosstalk between MUC1 and VEGF in angiogenesis and metastasis: a review highlighting roles of the MUC1 with an emphasis on metastatic and angiogenic signaling

  2021influential citation
• Screening of novel alkaloid inhibitors for vascular endothelial growth factor in cancer cells: an integrated computational approach

  2021cites this paper
• Effect of Normobaric Hyperoxia Preconditioning on VEGF and Endostatin Levels in the Rat Stroke Model

  2021cites this paper
• Discovery of Oral Anticancer 1,2-Bis(hydroxymethyl)benzo[g]pyrrolo[2,1-a]phthalazine Hybrids That Inhibit Angiogenesis and Induce DNA Cross-Links.

  2021cites this paper
• MAZ51 Blocks the Tumor Growth of Prostate Cancer by Inhibiting Vascular Endothelial Growth Factor Receptor 3

  2021cites this paper
• Nephrotoxicity induced by vascular endothelial growth factor inhibitors

  2021cites this paper